Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Cell Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR2DS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR2DS2 ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed for native glycosylation. |
View KIR2DS2 Products |
| Gene Delivery | KIR2DS2 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View KIR2DS2 Products |
| Benchmark Ab | Anti-KIR2DS2 Recombinant Antibody Recombinant positive control matching reference clinical sequences. |
View KIR2DS2 Products |
| Validator | KIR2DS2 siRNA Set For target knockdown validation in primary NK cells or reporter lines. |
View KIR2DS2 Products |
| Related Target A | KIR2DL2 Highly homologous inhibitory receptor; critical for selectivity counter-screening. |
View KIR2DL2 Products |
| Related Target B | HLA-C Natural ligand family; essential for competitive binding and functional assays. |
View HLA-C Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High sequence homology with inhibitory KIR2DL2/3 (risk of off-target binding) | Human KIR2DL2 and KIR2DL3 recombinant proteins available with >95% purity for stringent counter-screening panels |
| Low-affinity ligand interactions requiring native conformation | HEK293-expressed ECD-Fc proteins preserving native post-translational modifications and folding |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live KIR2DS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR2DS2 therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific NK cell engagers (NKCEs). As first-generation therapies reach the clinic, the next wave of R&D is targeting selective activation of NK cells while avoiding off-target inhibition via closely related inhibitory KIRs.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| NK Cell Engager (NKCE) | Innate Pharma, Affimed | Hematological Malignancies, Solid Tumors | Selectivity Assay (Need High-homology KIR2DL2/3 Counter-screening Proteins) |
| Agonistic Antibodies | Academic Institutions, Biotech Startups | Solid Tumors, Infectious Diseases | Activation Assay (Need Sequence-verified Lentivirus for Stable Reporter Lines) |
| CAR-NK / Cell Therapy | Various Biotechs | Refractory Solid Tumors | Conformation-specific binding validation (Need HEK293 Expressed Antigens) |